Clinical outcomes of the chemo-free approach in relapsed/refractory follicular lymphoma: A network meta-analysis.

What was studied

This review looked at drug plans for follicular lymphoma. The cancer had come back or did not respond. The plans had no chemo. They all used anti-CD20 antibodies. The team pooled trials with 2500 people. Main goals were overall survival and progression-free survival.

What they found

Plans that rouse the immune system ranked highest. Epcoritamab plus R2 ranked top for survival and response. Tafasitamab plus R2 ranked next. It also had a better safety profile. Plans with PI3K blockers had the weakest benefit-risk profile. Anti-CD20 alone was the safest. It was also the least effective.

What it means for patients

The team says immune-based plans with anti-CD20 were the most effective. These plans avoid chemo. Plans with bispecific antibodies appear to give deeper control of disease.

Why it is not certain yet

Rankings rest on indirect comparisons. The abstract does not give effect sizes. The abstract does not give follow-up times. The trials covered different phases. Some of the work is not described there. Full data tables are not shown. Some steps of the work are not given.

Source

Clinical outcomes of the chemo-free approach in relapsed/refractory follicular lymphoma: A network meta-analysis.

We restate facts from the source record in our own words. The original wording belongs to its publisher.